Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$111.29 USD

111.29
1,399,352

+0.65 (0.59%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

New Strong Sell Stocks for December 6th

by Zacks Equity Research

BYND, NVST, FSTR, ZBH, and PHR have been added to the Zacks Rank #5 (Strong Sell) List on December 6, 2021.

Zimmer Biomet's (ZBH) Recovery Slows in Americas Amid Pandemic

by Zacks Equity Research

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

New Strong Sell Stocks for November 9th

by Zacks Equity Research

MGLN, SAND, UFCS, WW, and ZBH have been added to the Zacks Rank #5 (Strong Sell) List on November 9, 2021.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, View Slashed

by Zacks Equity Research

Zimmer Biomet (ZBH) Q3 sales soft in Americas whereas EMEA and Asia-Pacific register growth at CER.

Zimmer Biomet (ZBH) Beats Q3 Earnings Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 3.43% and -1.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

Medical Products' Nov 4 Earnings Roster: BDX, ZBH & More

by Trina Mukherjee

The Medical Product companies' Q3 results are likely to reflect huge adoption of their COVID-related support products. Let's see how BDX, ZBH, ABC and XRAY are poised ahead of their earnings releases.

Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Strong surgeon registrations of the Signature One surgical planning system for shoulder procedures are likely to have driven Zimmer Biomet's (ZBH) growth in Q3.

Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space

by Debanjana Dey

OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.

Here's Why You Should Retain Globus Medical (GMED) for Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) owing to domestic growth in the spine business and robust demand for the HEDRON line of products.

Strength Seen in Zimmer (ZBH): Can Its 4.7% Jump Turn into More Strength?

by Zacks Equity Research

Zimmer (ZBH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zimmer Biomet (ZBH) Hurt by EMEA's Slow Recovery Amid Pandemic

by Zacks Equity Research

Zimmer Biomet's (ZBH) leveraged capital structure is an added concern.

Zimmer (ZBH) Up 1.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zimmer Biomet's (ZBH) Data Favors mymobility with Apple Watch

by Zacks Equity Research

Zimmer Biomet (ZBH) presented four data presentations backing the mymobility with Apple Watch platform at the AAOS 2021 Annual Meeting.

Zimmer Biomet (ZBH) Receives FDA Nod for ROSA Hip System

by Zacks Equity Research

The recent FDA go-ahead for Zimmer Biomet's (ZBH) ROSA Hip System will aid surgeons perform robotically-assisted direct anterior total hip replacement surgery.

Zimmer Biomet (ZBH) Recovery Rate Slows Down Amid Pandemic

by Zacks Equity Research

Zimmer Biomet (ZBH) sees slower recovery amid the emergence of a new strain of coronavirus in a number of markets, including Japan.

Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.

Zimmer Biomet (ZBH) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 3.26% and 2.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?

by Zacks Equity Research

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand

by Zacks Equity Research

Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.

LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)

by Zacks Equity Research

LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.

Is a Beat in Store for Zimmer Biomet (ZBH) in Q2 Earnings?

by Zacks Equity Research

Zimmer Biomet's (ZBH) S.E.T. is expected to have performed better than expected on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.

Zimmer Biomet (ZBH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest In Globus Medical (GMED) Now

by Zacks Equity Research

Strong first-quarter performance by the U.S. Spine and Enabling Technologies business contributed to Globus Medical's (GMED) top line.

LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)

by Zacks Equity Research

LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.